{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:04:17Z","timestamp":1793397857843,"version":"4.5.0"},"reference-count":106,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jaci.2022.04.003","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T21:03:48Z","timestamp":1649711028000},"page":"1866-1874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Drug-induced mast cell eradication: A\u00a0novel approach to treat mast cell activation disorders?"],"prefix":"10.1016","volume":"149","author":[{"given":"Peter","family":"Valent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Sotlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Degenfeld-Schonburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dubravka","family":"Smiljkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Triggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Horny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Arock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean D.","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2022.04.003_bib1","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.003_bib2","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/eji.201040559","article-title":"Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity","volume":"40","author":"Galli","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaci.2022.04.003_bib3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.04.003_bib4","doi-asserted-by":"crossref","first-page":"10743","DOI":"10.7150\/thno.46719","article-title":"Mast cells as a unique hematopoietic lineage and cell system: from Paul Ehrlich's visions to precision medicine concepts","volume":"10","author":"Valent","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jaci.2022.04.003_bib5","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.271.5250.818","article-title":"Identification of a committed precursor for the mast cell lineage","volume":"271","author":"Rodewald","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.jaci.2022.04.003_bib6","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1182\/blood.V93.10.3338.410k05_3338_3346","article-title":"Characterization of mast cell-committed progenitors present in human umbilical cord blood","volume":"93","author":"Kempuraj","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.003_bib7","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood.V94.7.2333.419k30_2333_2342","article-title":"Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13)","volume":"94","author":"Kirshenbaum","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.003_bib8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jaci.2013.02.011","article-title":"Human mast cells arise from a common circulating progenitor","volume":"132","author":"Maaninka","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.04.003_bib9","first-page":"5","article-title":"New insights into \"the riddle of the mast cells\": microenvironmental regulation of mast cell development and phenotypic heterogeneity","volume":"62","author":"Galli","year":"1990","journal-title":"Lab Invest"},{"key":"10.1016\/j.jaci.2022.04.003_bib10","first-page":"965","article-title":"The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others","volume":"142","author":"Galli","year":"1993","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaci.2022.04.003_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0167-5699(94)90153-8","article-title":"The riddle of the mast cell: kit(CD117)-ligand as the missing link?","volume":"15","author":"Valent","year":"1994","journal-title":"Immunol Today"},{"key":"10.1016\/j.jaci.2022.04.003_bib12","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.4049\/jimmunol.153.8.3717","article-title":"Stem cell factor is a chemotactic factor for human mast cells","volume":"153","author":"Nilsson","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2022.04.003_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaci.2004.04.046","article-title":"The biology of Kit in disease and the application of pharmacogenetics","volume":"114","author":"Akin","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.04.003_bib14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.pai.0000173054.83414.22","article-title":"KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation","volume":"13","author":"Miettinen","year":"2005","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.jaci.2022.04.003_bib15","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/all.12126","article-title":"Mast cell activation syndromes: definition and classification","volume":"68","author":"Valent","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.04.003_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11882-015-0582-5","article-title":"Hymenoptera allergy and mast cell activation syndromes","volume":"16","author":"Bonadonna","year":"2016","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaci.2022.04.003_bib17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-immunol-071719-094903","article-title":"Mast cells in inflammation and disease: recent progress and ongoing concerns","volume":"38","author":"Galli","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaci.2022.04.003_bib18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.iac.2021.09.007","article-title":"Anaphylaxis and mast cell disorders","volume":"42","author":"G\u00fclen","year":"2022","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2022.04.003_bib19","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.04.003_bib20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2022.04.003_bib21","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","article-title":"Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome","volume":"7","author":"Valent","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.04.003_bib22","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1172\/JCI114025","article-title":"Role of mast cells in anaphylaxis. Evidence for the importance of mast cells in the cardiopulmonary alterations and death induced by anti-IgE in mice","volume":"83","author":"Martin","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2022.04.003_bib23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000087644","article-title":"Using mast cell knock-in mice to analyze the roles of mast cells in allergic responses in\u00a0vivo","volume":"87","author":"Tsai","year":"2005","journal-title":"Chem Immunol Allergy"},{"key":"10.1016\/j.jaci.2022.04.003_bib24","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jaci.2013.06.008","article-title":"Selective ablation of mast cells or basophils reduces peanut-induced anaphylaxis in mice","volume":"132","author":"Reber","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.04.003_bib25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaci.2017.06.003","article-title":"The pathophysiology of anaphylaxis","volume":"140","author":"Reber","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.04.003_bib26","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41374-019-0354-2","article-title":"Development of multiple features of antigen-induced asthma pathology in a new strain of mast cell deficient BALB\/c-Kit(W-sh\/W-sh) mice","volume":"100","author":"Hernandez","year":"2020","journal-title":"Lab Invest"},{"key":"10.1016\/j.jaci.2022.04.003_bib27","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/cea.12318","article-title":"Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disorders","volume":"44","author":"Valent","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2022.04.003_bib28","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaip.2019.02.002","article-title":"Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management","volume":"7","author":"Castells","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.04.003_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.emc.2021.08.004","article-title":"Anaphylaxis: emergency department treatment","volume":"40","author":"McHugh","year":"2022","journal-title":"Emerg Med Clin North Am"},{"key":"10.1016\/j.jaci.2022.04.003_bib30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3810\/pgm.1996.08.51","article-title":"Anaphylaxis: how to recognize, treat and prevent potentially fatal attacks","volume":"100","author":"Wyatt","year":"1996","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jaci.2022.04.003_bib31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/ACI.0b013e32836097f4","article-title":"Glucocorticosteroids for the treatment and prevention of anaphylaxis","volume":"13","author":"Sheikh","year":"2013","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.04.003_bib32","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.3390\/ijms21239030","article-title":"Diagnosis, classification and management of mast cell activation syndromes (MCAS) in the era of personalized medicine","volume":"21","author":"Valent","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2022.04.003_bib33","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1398-9995.2009.02118.x","article-title":"Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy","volume":"64","author":"Niedoszytko","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.04.003_bib34","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaip.2013.06.014","article-title":"Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations","volume":"1","author":"Bonadonna","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.04.003_bib35","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/all.13237","article-title":"Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations","volume":"73","author":"Broesby-Olsen","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.04.003_bib36","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.jaip.2019.03.039","article-title":"Omalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS","volume":"7","author":"Lemal","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.04.003_bib37","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/cea.13592","article-title":"Omalizumab in the treatment of adult patients with mastocytosis: a systematic review","volume":"50","author":"Jendoubi","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2022.04.003_bib38","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.jaci.2020.11.005","article-title":"A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis","volume":"147","author":"Carter","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.04.003_bib39","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.04.003_bib40","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1056\/NEJMc1515403","article-title":"Midostaurin in advanced systemic mastocytosis","volume":"374","author":"Chandesris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.04.003_bib41","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jaci.2020.03.044","article-title":"Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis","volume":"146","author":"Hartmann","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.04.003_bib42","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1093\/annonc\/mdx290","article-title":"Midostaurin: a magic bullet that blocks mast cell expansion and activation","volume":"28","author":"Valent","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaci.2022.04.003_bib43","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2022.04.003_bib44","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2022.04.003_bib45","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1182\/blood.V52.2.447.447","article-title":"Decrease of mast cells in W\/Wv mice and their increase by bone marrow transplantation","volume":"52","author":"Kitamura","year":"1978","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.003_bib46","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/281154a0","article-title":"Clonal nature of mast-cell clusters formed in W\/Wv mice after bone marrow transplantation","volume":"281","author":"Kitamura","year":"1979","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2022.04.003_bib47","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1182\/blood.V84.9.2954.2954","article-title":"Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation","volume":"84","author":"F\u00f6dinger","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.003_bib48","doi-asserted-by":"crossref","first-page":"772","DOI":"10.4049\/jimmunol.148.3.772","article-title":"Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells","volume":"148","author":"Kirshenbaum","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2022.04.003_bib49","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1182\/blood.V80.9.2237.2237","article-title":"Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor\/kit-ligand in long-term culture","volume":"80","author":"Valent","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.003_bib50","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1182\/blood.V80.12.3009.3009","article-title":"Recombinant human stem cell factor stimulates differentiation of mast cells from dispersed human fetal liver cells","volume":"80","author":"Irani","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.003_bib51","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/BF02982123","article-title":"Cytokines regulate development of human mast cells from hematopoietic progenitors","volume":"75","author":"Nakahata","year":"2002","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jaci.2022.04.003_bib52","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4049\/jimmunol.157.1.343","article-title":"Selective growth of human mast cells induced by Steel factor, IL-6, and prostaglandin E2 from cord blood mononuclear cells","volume":"157","author":"Saito","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2022.04.003_bib53","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1084\/jem.190.2.267","article-title":"T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in\u00a0vitro","volume":"190","author":"Ochi","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2022.04.003_bib54","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.4049\/jimmunol.159.6.2911","article-title":"Effect of recombinant human IL-4 on tryptase, chymase, and Fc epsilon receptor type I expression in recombinant human stem cell factor-dependent fetal liver-derived human mast cells","volume":"159","author":"Xia","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2022.04.003_bib55","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/blood.V91.1.187","article-title":"Interleukin-4 promotes the development of tryptase and chymase double-positive human mast cells accompanied by cell maturation","volume":"91","author":"Toru","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.003_bib56","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.4049\/jimmunol.162.9.5455","volume":"162","author":"Yamaguchi","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2022.04.003_bib57","doi-asserted-by":"crossref","unstructured":"Alvarado D, Maurer M, Gedrich R, Seibel SB, Murphy MB, Crew L, et\u00a0al. Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study. Allergy https:\/\/doi.org\/10.1111\/all.15262. Accessed February 19, 2022","DOI":"10.1111\/all.15262"},{"key":"10.1016\/j.jaci.2022.04.003_bib58","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3324\/haematol.11339","article-title":"Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT","volume":"92","author":"Gleixner","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.jaci.2022.04.003_bib59","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood-2007-08-104372","article-title":"The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils","volume":"111","author":"Kneidinger","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.003_bib60","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4062\/biomolther.2020.013","article-title":"Dasatinib inhibits Lyn and Fyn Src-family kinases in mast cells to suppress type I hypersensitivity in mice","volume":"28","author":"Lee","year":"2020","journal-title":"Biomol Ther (Seoul)"},{"key":"10.1016\/j.jaci.2022.04.003_bib61","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1021\/acs.biochem.8b00727","article-title":"Comparison of the kinase profile of midostaurin (rydapt) with that of its predominant metabolites and the potential relevance of some newly identified targets to leukemia therapy","volume":"57","author":"Manley","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.jaci.2022.04.003_bib62","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2015.242","article-title":"Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth","volume":"30","author":"Peter","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2022.04.003_bib63","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1172\/JCI116761","article-title":"Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product","volume":"92","author":"Furitsu","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2022.04.003_bib64","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2022.04.003_bib65","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1189\/jlb.0602284","article-title":"STI571 inhibits growth and adhesion of human mast cells in culture","volume":"74","author":"Takeuchi","year":"2003","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jaci.2022.04.003_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007258","article-title":"Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT","volume":"4","author":"Dubreuil","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2022.04.003_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052564","article-title":"Imatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cells","volume":"7","author":"Belle","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2022.04.003_bib68","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.18632\/oncotarget.3074","article-title":"Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia","volume":"6","author":"Cerny-Reiterer","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaci.2022.04.003_bib69","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT\u00a0mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.003_bib70","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","article-title":"PKC412 inhibits in\u00a0vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects","volume":"107","author":"Gleixner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.003_bib71","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3324\/haematol.2017.179895","article-title":"The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis","volume":"103","author":"Schneeweiss","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jaci.2022.04.003_bib72","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41375-019-0450-8","article-title":"Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis","volume":"33","author":"L\u00fcbke","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2022.04.003_bib73","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood.2019004509","article-title":"Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis","volume":"137","author":"Toledo","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.003_bib74","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s00432-015-1988-0","article-title":"Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study","volume":"141","author":"Hochhaus","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jaci.2022.04.003_bib75","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial","volume":"107","author":"Droogendijk","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.jaci.2022.04.003_bib76","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaci.2022.04.003_bib77","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2022.04.003_bib78","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.leukres.2011.05.006","article-title":"Tyrosine kinase inhibitors in the treatment of systemic mastocytosis","volume":"35","author":"Ustun","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2022.04.003_bib79","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11899-018-0469-3","article-title":"Clinical validation of KIT inhibition in advanced systemic mastocytosis","volume":"13","author":"Baird","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.jaci.2022.04.003_bib80","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.2019000932","article-title":"New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis","volume":"135","author":"Reiter","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.003_bib81","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jaci.2018.06.003","article-title":"Midostaurin in patients with indolent systemic mastocytosis: an open-label phase 2 trial","volume":"142","author":"van Anrooij","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.04.003_bib82","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.003_bib83","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.leukres.2005.08.015","article-title":"A novel K509I mutation of KIT identified in familial mastocytosis-in\u00a0vitro and in\u00a0vivo responsiveness to imatinib therapy","volume":"30","author":"Zhang","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2022.04.003_bib84","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.leukres.2014.07.010","article-title":"Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412","volume":"38","author":"de Melo Campos","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2022.04.003_bib85","first-page":"93","article-title":"Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT","volume":"4","author":"Valent","year":"2014","journal-title":"Am J Blood Res"},{"key":"10.1016\/j.jaci.2022.04.003_bib86","doi-asserted-by":"crossref","first-page":"68950","DOI":"10.18632\/oncotarget.10711","article-title":"Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature","volume":"8","author":"Alvarez-Twose","year":"2016","journal-title":"Oncotarget"},{"issue":"suppl\u00a01","key":"10.1016\/j.jaci.2022.04.003_bib87","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1182\/blood-2021-152770","article-title":"Preclinical data with KIT D816V inhibitor bezuclastinib (CGT9486) demonstrates high selectivity and minimal brain penetrance","volume":"138","author":"Guarnieri","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.003_bib88","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/j.jaip.2021.02.040","article-title":"Systemic mastocytosis with an associated hematologic neoplasm complicated by recurrent anaphylaxis: prompt resolution of anaphylaxis with the addition of avapritinib","volume":"9","author":"Kudlaty","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.04.003_bib89","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/intimm\/8.9.1367","article-title":"Induction of the high-affinity IgE receptor (Fc epsilon RI) on human mast cells by IL-4","volume":"8","author":"Toru","year":"1996","journal-title":"Int Immunol"},{"key":"10.1016\/j.jaci.2022.04.003_bib90","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1084\/jem.175.1.237","article-title":"c-kit ligand: a unique potentiator of mediator release by human lung mast cells","volume":"175","author":"Bischoff","year":"1992","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2022.04.003_bib91","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000236568","article-title":"Specific activation of human mast cells by the ligand for c-kit: comparison between lung, uterus and heart mast cells","volume":"102","author":"Sperr","year":"1993","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2022.04.003_bib92","doi-asserted-by":"crossref","first-page":"599","DOI":"10.4049\/jimmunol.149.2.599","article-title":"The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils","volume":"149","author":"Columbo","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2022.04.003_bib93","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1084\/jem.183.6.2681","article-title":"Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in\u00a0vivo","volume":"183","author":"Costa","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2022.04.003_bib94","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.1365-2222.2009.03353.x","article-title":"Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells","volume":"39","author":"Krauth","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2022.04.003_bib95","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1046\/j.1365-2133.2001.04224.x","article-title":"Serum levels of soluble stem cell factor and soluble KIT are elevated in patients with atopic dermatitis and correlate with the disease severity","volume":"144","author":"Kanbe","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2022.04.003_bib96","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000087642","article-title":"Potential role of stem cell factor in the asthma control by glucocorticoids","volume":"87","author":"Da Silva","year":"2005","journal-title":"Chem Immunol Allergy"},{"key":"10.1016\/j.jaci.2022.04.003_bib97","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1398-9995.2007.01566.x","article-title":"SCF and IL-31 rather than IL-17 and BAFF are potential indicators in patients with allergic asthma","volume":"63","author":"Lei","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.04.003_bib98","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12931-017-0504-2","article-title":"Association of stem cell factor gene expression with severity and atopic state in patients with bronchial asthma","volume":"18","author":"Tayel","year":"2017","journal-title":"Respir Res"},{"key":"10.1016\/j.jaci.2022.04.003_bib99","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1159\/000335122","article-title":"The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma","volume":"158","author":"Lee-Fowler","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2022.04.003_bib100","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1111\/j.1365-2982.2012.01941.x","article-title":"Imatinib mesylate alleviates diarrhea in a mouse model of intestinal allergy","volume":"24","author":"Vaali","year":"2012","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.jaci.2022.04.003_bib101","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/bjd.12069","article-title":"Topical administration of the pan-Src kinase inhibitors, dasatinib and LCB 03-0110, prevents allergic contact dermatitis in mice","volume":"168","author":"Jung","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2022.04.003_bib102","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/bph.13430","article-title":"The tyrosine kinase inhibitor dasatinib reduces lung inflammation and remodelling in experimental allergic asthma","volume":"173","author":"da Silva","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaci.2022.04.003_bib103","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/j.1398-9995.2009.02122.x","article-title":"Masitinib, a c-kit\/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics","volume":"64","author":"Humbert","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.04.003_bib104","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1056\/NEJMoa1613125","article-title":"KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma","volume":"376","author":"Cahill","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.04.003_bib105","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jaci.2012.05.039","article-title":"Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy","volume":"130","author":"Savage","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.04.003_bib106","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMe1702653","article-title":"Mast cells and KIT as potential therapeutic targets in severe asthma","volume":"376","author":"Galli","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674922004511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674922004511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:37:01Z","timestamp":1758793021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674922004511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":106,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0091674922004511"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2022.04.003","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced mast cell eradication: A\u00a0novel approach to treat mast cell activation disorders?","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2022.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}